Basic Information
| LncRNA/CircRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p17AS |
| Region | GRCh38_9:21994778-22121097 |
| Ensemble | ENSG00000240498 |
| Refseq | NR_003529 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, Luciferase reporter assay, other |
| Sample | CRC tisues and cell lines (LOVO, HCT116,HT29, RKO, SW480) |
| Expression Pattern | up-regulated |
| Function Description | Increased ANRIL expression in CRC was associated with poor clinical prognosis. Kaplan-Meier analysis showed that ANRIL was associated with overall survival of patients with colorectal cancer, and patients with high ANRIL expression tended to have unfavorable outcome. In vitro experiments revealed that ANRIL knockdown significantly inhibited CRC cell proliferation, improved the sensitivity of chemotherapy and promoted apoptosis. Further functional assays indicated that ANRIL overexpression significantly promoted cell chemoresistance by regulating ATP-binding cassette subfamily C member 1 through binding Let-7a. |
| Pubmed ID | 30279206 |
| Year | 2018 |
| Title | ANRIL Promotes Chemoresistance via Disturbing Expression of ABCC1 by Regulating the Expression of Let-7a in Colorectal Cancer |
External Links
| Links for ANRIL | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |